Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Patterns and Predictors of Emicizumab Adherence in People with Hemophilia

Ang Li, MD, Catlin Goodfriend, PharmD, John Sokol, PharmD, Rebecca Kruse-Jarres, MDMPH

Blood (2019) 134 (Supplement_1): 2178.

https://doi.org/10.1182/blood-2019-128083

Published: 2019

Journal Articles

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Marianne Kjalke, PhD, Mads Kjelgaard-Hansen, Søren Andersen, Ida Hilden

Blood (2019) 134 (Supplement_1): 3639.

https://doi.org/10.1182/blood-2019-122301

Published: 2019

Journal Articles

Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis

Ammon Fager, MD PhD, Maureane Hoffman, MD PhD, Dougald Monroe, PhD

Blood (2019) 134 (Supplement_1): 3623.

https://doi.org/10.1182/blood-2019-124428

Published: 2019

Journal Articles

CCL2 Promotes Macrophages-Associated Chemoresistance Via MCPIP1 Dual Catalytic Activities in Multiple Myeloma

Ruyi Xu, Yi Li, MD, Haimeng Yan, MD, Xi Huang, MD, He Huang, MD PhD, Zhen Cai, MD PhD

Blood (2019) 134 (Supplement_1): 3086.

https://doi.org/10.1182/blood-2019-126498

Published: 2019

Journal Articles

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Patrick T. Ebbert, BS, Frederico Xavier, MD MS, Craig D. Seaman, MD MS, Margaret V. Ragni, MD MPH

Blood (2019) 134 (Supplement_1): 2416.

https://doi.org/10.1182/blood-2019-123198

Published: 2019

Journal Articles

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events

Steven Pipe, MD, Margaret V. Ragni, MD MPH, Claude Négrier, MD PhD, Qifeng Yu, PhD, Naghmana Bajwa, MD, John Caminis, MD, Baisong Mei, MD PhD, Shauna R. Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 1138.

https://doi.org/10.1182/blood-2019-124108

Published: 2019

Journal Articles

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Robert F. Sidonio, Jr., MD MSc, Bruce A. Schwartz, PhD

Blood (2019) 134 (Supplement_1): 4931.

https://doi.org/10.1182/blood-2019-128339

Published: 2019

Journal Articles

Unexpected Concomitance of BCR-ABL and PML-Rarα Leukemia - Three-Year Follow-up

Caique Pereira de Moura Martins, MDcal Student, João Vítor Ternes Rech, MDcal Student, Lee I-Ching, MD, Giovanna Steffenello Durigon, MD, Joanita Angela Del Moral, MD, Mirella Rodrigues Oliveira, MD, Bruno Vieira Dias, Maria Claudia Santos, PhD, Andressa Oliveira Martin Wagner, André Guedes Vieira

Blood (2019) 134 (Supplement_1): 5038.

https://doi.org/10.1182/blood-2019-132259

Published: 2019

Journal Articles

Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib

Alexander Vdovin, Tomas Jelinek, MD, Matous Hrdinka, PhD, Juli R. Bago, PhD, Tereza Sevcikova, Roman Hajek, Prof, MD PhD, Michal Simicek, PhD

Blood (2019) 134 (Supplement_1): 5526.

https://doi.org/10.1182/blood-2019-127930

Published: 2019

Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Michael Callaghan, MD, Benjamin Trzaskoma, MS, Richard H. Ko, MD, Lucy Lee, PharmD, Anisha M. Patel, PhD, Eunice Tzeng, PharmD, Michelle Lynn Shah, PharmD, Tiffany Y. Chang, MD MAS, Markus Niggli, PhD, Christophe Dhalluin, PhD, Johnny Mahlangu, MMed, FCPath

Blood (2019) 134 (Supplement_1): 2395.

https://doi.org/10.1182/blood-2019-123654

Published: 2019

Journal Articles

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays

Hande Kizilocak, Elizabeth Marquez-Casas, BS, Jemily Malvar, MS, Roxana Carmona, MD, Guy Young, MD

Blood (2019) 134 (Supplement_1): 904.

https://doi.org/10.1182/blood-2019-132050

Published: 2019

Journal Articles

Inhibitor Development with Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia a: Final Results of the Nuprotect Study

Ri Liesner, Ellis J. Neufeld, MD

Blood (2019) 134 (Supplement_1): 903.

https://doi.org/10.1182/blood-2019-125520

Published: 2019

Journal Articles

The BRISC deubiquitinating enzyme complex limits hematopoietic stem cell expansion by regulating JAK2 K63-ubiquitination

Ryan Donaghy, Xu Han, Krasimira Rozenova, Kaosheng Lv, Qinqin Jiang, Miriam Doepner, Roger A. Greenberg, Wei Tong

Blood (2019) 133 (14): 1560–1571.

https://doi.org/10.1182/blood-2018-10-877563

Published: 2019

Includes: Supplemental data

Journal Articles

New therapies for hemophilia

Angela C. Weyand, Steven W. Pipe

Blood (2019) 133 (5): 389–398.

https://doi.org/10.1182/blood-2018-08-872291

Published: 2019

Journal Articles

A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia

Michael A Suster, PhD, Debnath Maji, M.Tech, Lalitha V. Nayak, MD, Christina Jenkins, MSN-PNP, RN, Susan Hunter, BSN, RN-BC, Alvin H. Schmaier, MD, Pedram Mohseni, PhD, Sanjay Ahuja

Blood (2018) 132 (Supplement 1): 2475.

https://doi.org/10.1182/blood-2018-99-113623

Published: 2018

Journal Articles

Opportunities for Improvement: The Lot of the Inhibitor Patient Is Not a Happy One

Frank V. McL. Booth, MA MSc BM BCh, Johnny Mahlangu, Howard Levy, PhD MBBChir

Blood (2018) 132 (Supplement 1): 5040.

https://doi.org/10.1182/blood-2018-99-111720

Published: 2018

Journal Articles

A Novel Approach to Immune Tolerance Induction in Hemophilia Α with Factor VIII Inhibitor

Courtney D. Thornburg, MD, Jonathan M. Ducore, MD

Blood (2018) 132 (Supplement 1): 5042.

https://doi.org/10.1182/blood-2018-99-119800

Published: 2018

Journal Articles

Biochemical Characteristics of Emicizumab Activity with Factors IXa, X, and VIIa

Dougald Monroe, PhD, Maureane Hoffman, MD

Blood (2018) 132 (Supplement 1): 1167.

https://doi.org/10.1182/blood-2018-99-116888

Published: 2018

Journal Articles

The Efficacy of Ultrasound Joint Examination for the Management in Patients with Hemophilia

Shiho Nishimura, MD, Keita Tomioka, MD, Maiko Shimomura, MD, Yoko Mizoguchi, MD PhD, Shinobu Sasaki, Chihiro Tani, MD PhD, Yoshiko Matsubara, Kazuo Awai, MD PhD, Yuko Nakashima, MD PhD, Nobuo Adachi, MD PhD, Masao Kobayashi, MD PhD

Blood (2018) 132 (Supplement 1): 5027.

https://doi.org/10.1182/blood-2018-99-120016

Published: 2018

Journal Articles

Elucidating the Excessive Pro-Coagulant Effect of a Sequence Identical Analogue to ACE910 in Combination with Bypassing Agents

Rudolf Hartmann, PhD, Tjerk Feenstra, MSc, Sabine Knappe, PhD, Michael Dockal, PhD, Friedrich Scheiflinger, PhD

Blood (2017) 130 (Supplement 1): 90.

https://doi.org/10.1182/blood.V130.Suppl_1.90.90

Published: 2017

NARROW

Patterns and Predictors of Emicizumab Adherence in People with Hemophilia

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis

CCL2 Promotes Macrophages-Associated Chemoresistance Via MCPIP1 Dual Catalytic Activities in Multiple Myeloma

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute Bleeding Events

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Unexpected Concomitance of BCR-ABL and PML-Rarα Leukemia - Three-Year Follow-up

Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays

Inhibitor Development with Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia a: Final Results of the Nuprotect Study

The BRISC deubiquitinating enzyme complex limits hematopoietic stem cell expansion by regulating JAK2 K63-ubiquitination

New therapies for hemophilia

A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia

Opportunities for Improvement: The Lot of the Inhibitor Patient Is Not a Happy One

A Novel Approach to Immune Tolerance Induction in Hemophilia Α with Factor VIII Inhibitor

Biochemical Characteristics of Emicizumab Activity with Factors IXa, X, and VIIa

The Efficacy of Ultrasound Joint Examination for the Management in Patients with Hemophilia

Elucidating the Excessive Pro-Coagulant Effect of a Sequence Identical Analogue to ACE910 in Combination with Bypassing Agents

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only